The EU's joint assessment is a starting gun for national work, not a finish line

A new document type has arrived

On 6 November the Commission published the joint clinical assessment report on camizestrant (Etcamah) for breast cancer. Austria and Belgium prepared it under the EU HTA Regulation, and Member States endorsed it on 19 August 2026. The Commission says the report will feed into national decision-making.

That last phrase matters most. Our records do not say what the report concluded, and nobody should guess. What they do establish is the structure: a shared clinical assessment, produced centrally, handed to national systems that still decide for themselves. Publication came almost eleven weeks after endorsement, a gap planning teams should note.

The national layer has not gone anywhere

The same week's records show how much machinery sits downstream of any European assessment. Italy's AIFA opened a monitoring registry for Voranigo, with reimbursed use possible from 6 November. It also revised registries for Rybrevant, Imfinzi and Enhertu, adding dosing regimens, a chemotherapy combination and a change to a treatment block. Each of these is a national instrument with its own clinical definitions.

In the UK, the MHRA has opened a new cycle of its MHRA-NICE real-world evidence scientific dialogue, now an established service after a pilot. Across the Atlantic, CMS has finalised a permanent framework for Medicare drug price negotiation from 2029. Each system is building its own rulebook for what counts as value, and the joint assessment sits alongside these systems without replacing them.

My position is that the JCA will not simplify an access team's work. It adds a new, early, public clinical document that every payer can read, and it does nothing to remove the downstream local work.

The strongest counter-argument

The best case against this view is that harmonisation is the whole point. If Member States rely on one clinical assessment, duplicate appraisals shrink, and teams can write one evidence story instead of many. That could prove true over time, and the Commission's framing supports the intent.

But intent is not yet evidence of behaviour. We do not know how national bodies will use the report, what weight it will carry in each pricing process, or how it will interact with local requirements like registries and real-world evidence commitments. Until we see this across several assessments, assuming convergence is a bet. The costlier error would be to stand down national workstreams while waiting for the JCA to settle the question.

What a sensible team does now

The practical risk is sequencing. A published JCA report becomes a fixed reference point that payers, clinicians and competitors can cite. Any gap between it and your national submissions then becomes visible. Teams need a deliberate translation step that maps the report's clinical content onto each priority market's requirements: the comparator choices, the evidence that local bodies ask for, and any monitoring obligations that follow reimbursement.

That step should start at endorsement, not publication. Endorsement on 19 August and publication on 6 November left a window of roughly eleven weeks. A team that waited for the public document lost that window.

Recommendation

Appoint one owner for the JCA-to-national translation, and give them a standing matrix: for each priority market, what the national body needs, what the JCA report supplies, and what remains to be generated locally. Review it each time a JCA report is endorsed, and treat the camizestrant report as the first live test of how well it works. — The Editor, VigiEye